Best Health Care Stocks to Watch in February 2025 | Global News Avenue

Knowledge about the health care department

The health care department is the popularity of COVID-19-19 and has not yet fully recovered. The industry continues to face serious labor shortages, which has been intensified by continuous inflation. The change of important elements of health care operations (from face -to -face medical appointments to changes in the needs of insurance and new products) forced long -term leaders to re -evaluate their products in this field and propose vacancies in order to make emerging companies foothold. Looking forward to the future, the health care department will fight for the population of patients who are increasingly qualified to get Medicaid and Medicare. Opportunity provided by AIAnd more.

A trend that investors pay close attention to is the continuous popularization of GLP-1 agonists. This is a drug for treating type 2 diabetes and helping to lose weight. About 1 billion people in the world have obesity, and the potential markets of these drugs are very large. The two main providers of these drugs are Novo Nordisk A/S (Non -governmental organization) Eli Lilly and Co. (Liberal), But the market is far from this.

How do we choose the best health care stocks

To screen the best medical stocks this month, we checked the company listed on any family Nasdaq or New York Stock ExchangeEssence In order to ensure that we focus on mature companies, we filter the company with a stock price of less than $ 5 except for any company. The minimum daily transaction volume is less than $ 100,000, and the market value is less than 300 million US dollars. From the stock group, we ranked the company based on the highest return of 30 days.

It is worth noting that there is no company’s price -earnings ratio in our results. One of the most common reasons for the company’s has no price -earnings ratio is that if there is no loss or no income for comparison within the given time period or during the last year. This makes it impossible to calculate the price -earnings ratio. For the clinical pharmaceutical company, many of them continue to or have always released losses when developing products, and usually have no price -earnings ratio before launching important drugs.

Healthcare stock advantages and disadvantages

The national health expenditure reached $ 4.9 trillion in 2023, making the medical department huge. The key benefits provided by medical care for investors are consistent needs. Because individuals will always meet medical care, the overall demand for health products and services will remain constant, and as the population increases, it will often increase with the passage of time. By 2030, national health care expenditures are expected to increase to $ 6.8 trillion.

Healthcare Company The reason why they attract investors is that they have highly inspired the use and creation of new technologies, which can not only meet the demand for rising demand, but also improve the nursing capabilities they can provide. Pay attention to innovation may mean the potential of short -term and long -term returns for medical and health stocks.

In the industry, when various companies launch important new products (such as new medical equipment with a wide range of applications or new bombs), even clinical trial data is encouraged, it is very common. At these moments, healthcare stocks often experience astronomical assemblies.

On the other hand, investment companies should also be aware of some risks of healthcare companies. One of the biggest risks is the scale and scope of the industry. Due to the technical nature of many medical care companies, it is difficult for external investors to accurately evaluate the feasibility of the company or their products. In addition, many companies in this field are seriously affected by legislation, which may change and lead to fluctuations.

There is no doubt that there is a chance to return to investors in the health care department. However, no one can predict the company’s stock performance. The company leads the industry on our screen, but the past performance is not a guarantee of future income.

Bottom line

The health care department is huge, complex and rich, and provides investors with the opportunity to spend time to understand its source. Our screen is conducive to a wealth of rewards in the field of drugs in the field of drugs last month, and occasionally due to the success of popular drugs or other products. However, just like some of them may rise rapidly, they may also decrease sharply, especially if there are hopeful new products that cannot work properly in the end.

Regarding the comments expressed in InvestOpeDia, viewpoints and analysis are only used for information purposes. Reading us Warranty and responsibility exemption statement More information.

As of the writing of this article, the author does not have any of the above securities.